TherapeuticsMD (TXMD) Amortization of Deferred Charges (2011 - 2022)

TherapeuticsMD has reported Amortization of Deferred Charges for 8 years, with the latest figure at $2.6 million in Q3 2022.

• For the quarter ending Q3 2022, Amortization of Deferred Charges rose 74.81% year-over-year to $2.6 million; the trailing twelve-month figure through Sep 2022 stood at $21.1 million (up 317.92% YoY), and the FY2021 full-year result was $5.7 million, up 124.68% from the prior year.
• Amortization of Deferred Charges for Q3 2022 stood at $2.6 million, down from $7.9 million in the prior quarter.
• The five-year high for Amortization of Deferred Charges was $9.0 million in Q1 2022, with the low at $119753.0 in Q3 2018.
• Historically, Amortization of Deferred Charges has averaged $1.7 million across 5 years, with a median of $887000.0 in 2020.
• Annual changes were most pronounced in 2021 — Amortization of Deferred Charges jumped 54.98% — and 2022, when it soared 611.32%.
• TherapeuticsMD's Amortization of Deferred Charges stood at $119950.0 in 2018, then surged by 127.74% to $273171.0 in 2019, then soared by 224.71% to $887000.0 in 2020, then jumped by 72.6% to $1.5 million in 2021, then surged by 68.65% to $2.6 million in 2022.
• The last three Amortization of Deferred Charges figures came in at $2.6 million (Q3 2022), $7.9 million (Q2 2022), and $9.0 million (Q1 2022), per Business Quant data.